Sign up to save your podcasts
Or
Share Donanemab’s Promise, BIO Wrap and Mass Layoffs
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Donanemab’s Promise, BIO Wrap and Mass Layoffs
The big news of this week so far was Monday’s FDA advisory committee for Eli Lilly’s Alzheimer’s drug donanemab, where the vote was unanimous in support of the anti-amyloid antibody. If approved, donanemab would be a direct competitor of Biogen and Eisai’s Leqembi, but analysts believe there’s plenty of room in the market for
both, and even predict that donanemab’s potential approval could be beneficial for Leqembi in the long run by increasing investments in advocacy and infrastructure.
The mood was decidedly different from last week’s FDA
adcomm, which voted overwhelmingly against approving Lykos Therapeutics’ MDMA-assisted PTSD therapy. Interestingly, that vote came down less an hour before BioSpace Senior Editor Heather McKenzie hosted a panel at BIO where Dan Karlin, chief medical officer at MindMed, said he’d hoped the conversation would have been different.
In other conference news, Eli Lilly and partners Boehringer Ingelheim and Zealand Pharma presented mid-stage results for their GLP-1 products in the MASH space at the Congress of the European Association for the Study of the Liver. These companies are eyeing a piece of the MASH market that Madrigal Pharmaceuticals first tapped into earlier this year when its therapy, Rezdiffra, was approved in March.
Finally, CBRE published a report on challenges in finding R&D and manufacturing talent, and thousands of layoffs continue to hit the biopharma industry. According to our Layoff Tracker, there have been 14,000 positions cut this year, with BMS and Bayer being the unfortunate leaders, each with more than 1,500 layoffs underway. Still, analysts
are optimistic that the second half of 2024 could be better, as an uptick in the financial markets might provide companies with money to spend on growing their workforces.
View all episodes
By BioSpace
4.9
1313 ratings
The big news of this week so far was Monday’s FDA advisory committee for Eli Lilly’s Alzheimer’s drug donanemab, where the vote was unanimous in support of the anti-amyloid antibody. If approved, donanemab would be a direct competitor of Biogen and Eisai’s Leqembi, but analysts believe there’s plenty of room in the market for
both, and even predict that donanemab’s potential approval could be beneficial for Leqembi in the long run by increasing investments in advocacy and infrastructure.
The mood was decidedly different from last week’s FDA
adcomm, which voted overwhelmingly against approving Lykos Therapeutics’ MDMA-assisted PTSD therapy. Interestingly, that vote came down less an hour before BioSpace Senior Editor Heather McKenzie hosted a panel at BIO where Dan Karlin, chief medical officer at MindMed, said he’d hoped the conversation would have been different.
In other conference news, Eli Lilly and partners Boehringer Ingelheim and Zealand Pharma presented mid-stage results for their GLP-1 products in the MASH space at the Congress of the European Association for the Study of the Liver. These companies are eyeing a piece of the MASH market that Madrigal Pharmaceuticals first tapped into earlier this year when its therapy, Rezdiffra, was approved in March.
Finally, CBRE published a report on challenges in finding R&D and manufacturing talent, and thousands of layoffs continue to hit the biopharma industry. According to our Layoff Tracker, there have been 14,000 positions cut this year, with BMS and Bayer being the unfortunate leaders, each with more than 1,500 layoffs underway. Still, analysts
are optimistic that the second half of 2024 could be better, as an uptick in the financial markets might provide companies with money to spend on growing their workforces.
More shows like BioSpace
View all
This American Life
90,820 Listeners
Planet Money
30,817 Listeners
Hidden Brain
43,710 Listeners
Marketplace
8,749 Listeners
Exchanges
951 Listeners
WSJ What’s News
4,357 Listeners
Bloomberg Surveillance
1,173 Listeners
Odd Lots
1,964 Listeners
Up First from NPR
56,830 Listeners
The Indicator from Planet Money
9,568 Listeners
The Readout Loud
323 Listeners
The Journal.
6,068 Listeners
Short Wave
6,566 Listeners
BioCentury This Week
34 Listeners
Biotech Hangout
21 Listeners